Integrated Genomics and GATC Renew License of ERGO™ Database to Degussa

CHICAGO, IL and Konstanz, Germany - December 4, 2005

Integrated Genomics Inc., a leading provider of bioinformatics tools, and GATC Biotech AG, have licensed Integrated Genomics' proprietary ERGO™ database and genomic discovery system to Degussa AG. Under the terms of the agreement, Scientists of Degussa's Project House ProFerm will use the ERGO™ system to optimise their production strains and find new methods of high yield production of amino acids and other specialty chemicals.

Optimized for analysis of micro-organisms, ERGO™ integrates biological data from genomics, biochemistry, gene expression studies, genetics and literature. Reaching beyond conventional systems for functional analysis of DNA sequences, Integrated Genomics' platform combines pattern-based analysis with comparative genomics and enables visualization of genes in the contexts of regulation, gene expression data, phylogeny, chromosomal neighborhoods and identification of natural gene fusions. ERGO™ contains more than 900 genomes at various stages of completion, as well as the largest available collection of networked cellular pathways.

"We have found the ERGO discovery system an exceptionally useful tool for our metabolic engineering projects, and expect that it will assist us in developing new production strains for higher and more cost effective productions of biological compounds," said Dr. Stefan Buchholz, Head of The Project House ProFerm at Degussa.

"GATC and Integrated Genomics are pleased to work with scientists at Degussa in this important new field of white biotechnology," said Peter Pohl, CEO of GATC Biotech AG. "We are confident that the ERGO platform will contribute to the understanding and improvement of their production strains."

Degussa, Integrated Genomics and GATC expect the current project to run through 2006.

About Integrated Genomics
Integrated Genomics is a provider of bioinformatics products and services for the life science industry, with a recent focus on the use of in silico strategies for metabolic engineering of microbes in the chemical, food, and agricultural industries. The company's expertise in microbial genomics includes genome sequencing, genome analysis and custom bioinformatics. In recent years IG has developed and distributed ERGO™, the most advanced and comprehensive bioinformatics suite for microbial genomics on the market. ERGO™ contains the largest available integration of microbial genome data, including genome-derived metabolic reconstructions and representing the chemical reaction networks of metabolic pathways.

About GATC Biotech
GATC Biotech, with headquarters in Constance, Germany, is a leading provider of molecular biological services and innovative bioinformatics solutions for industry and academia worldwide. GATC's portfolio contains services in the areas of genome sequencing, high throughput and custom sequencing, transcriptomics and functional analysis, complemented by a wide range of bioinformatic software, e.g. LasergeneT (DNA sequence analysis software) by DNASTAR Inc., ERGOT (Genome Analysis Suite) by Integrated Genomics, as well as Mutation SurveyorT/Mutation ExplorerT (DNA variant analysis software) and GeneMarkerT (Software for AFLP and genotyping) by SoftGenetics. Today, GATC has 45 employees and serves 3000 customers in 40 countries. This year GATC celebrates its 15th anniversary. Most of GATC's employees are scientists with long-term experience in biotechnology, molecular biology and chemistry. GATC has subsidiaries in Cambridge (UK) and Marseille (F) as well as offices in Tagerwilen (CH), Edinbourgh (UK), Munich and Hamburg. The company is ISO-certified since 1997.

About Degussa
Degussa is the global market leader in specialty chemicals. Our innovative products and system solutions make an indispensable contribution to our customers' success, which we sum up by our claim "creating essentials". In fiscal 2004 Degussa's 45,000 employees worldwide generated sales of 11.2 billion euros and operating profits(EBIT) of 965 million euros.

Vinayak Kapatral, Ph.D.
Vice President, Business Development
Integrated Genomics
(312) 491-0846 ext.326